- Home
- OTLK vs DYAI Comparison
OTLK vs DYAI Comparison
Compare OTLK & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- DYAI
- Stock Information
- Founded
- OTLK 2010
- DYAI 1979
- Country
- OTLK United States
- DYAI United States
- Employees
- OTLK N/A
- DYAI N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OTLK Health Care
- DYAI Health Care
- Exchange
- OTLK Nasdaq
- DYAI Nasdaq
- Market Cap
- OTLK 56.3M
- DYAI 54.4M
- IPO Year
- OTLK 2016
- DYAI 2004
- Fundamental
- Price
- OTLK $1.48
- DYAI $1.42
- Analyst Decision
- OTLK Strong Buy
- DYAI Strong Buy
- Analyst Count
- OTLK 5
- DYAI 1
- Target Price
- OTLK $10.20
- DYAI $6.00
- AVG Volume (30 Days)
- OTLK 479.6K
- DYAI 36.8K
- Earning Date
- OTLK 02-14-2025
- DYAI 03-27-2025
- Dividend Yield
- OTLK N/A
- DYAI N/A
- EPS Growth
- OTLK N/A
- DYAI N/A
- EPS
- OTLK N/A
- DYAI N/A
- Revenue
- OTLK N/A
- DYAI $3,364,548.00
- Revenue This Year
- OTLK N/A
- DYAI $51.30
- Revenue Next Year
- OTLK $288.46
- DYAI $73.26
- P/E Ratio
- OTLK N/A
- DYAI N/A
- Revenue Growth
- OTLK N/A
- DYAI 13.82
- 52 Week Low
- OTLK $0.87
- DYAI $0.93
- 52 Week High
- OTLK $12.85
- DYAI $2.67
- Technical
- Relative Strength Index (RSI)
- OTLK 40.05
- DYAI 44.20
- Support Level
- OTLK $1.38
- DYAI $1.37
- Resistance Level
- OTLK $1.51
- DYAI $1.54
- Average True Range (ATR)
- OTLK 0.12
- DYAI 0.12
- MACD
- OTLK 0.02
- DYAI -0.00
- Stochastic Oscillator
- OTLK 38.86
- DYAI 28.57
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About DYAI Dyadic International Inc.
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.